OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more
OUTLOOK THERAPEUTICS INC (OTLK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.000x
Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has a cash flow conversion efficiency ratio of 0.000x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.38 Million) by net assets ($-32.19 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OUTLOOK THERAPEUTICS INC - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OUTLOOK THERAPEUTICS INC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fast Food Indonesia Tbk
JK:FAST
|
-8.197x |
|
Security Bancorp Inc
PINK:SCYT
|
0.037x |
|
Graphex Group Limited
NYSE MKT:GRFX
|
-0.002x |
|
8AV0
F:8AV0
|
0.071x |
|
American Realty Investors Inc
NYSE:ARL
|
0.010x |
|
Neo Cremar Co. Ltd
KQ:311390
|
0.024x |
|
Arianne Phosphate Inc
OTCQX:DRRSF
|
-0.019x |
|
Vortex Consolidated Bhd
KLSE:0060
|
-0.077x |
Annual Cash Flow Conversion Efficiency for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual cash flow conversion efficiency of OUTLOOK THERAPEUTICS INC from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $-32.19 Trillion | $-51.83 Trillion | 1.610x | +71.05% |
| 2024-09-30 | $-73.08 Million | $-68.79 Million | 0.941x | -68.37% |
| 2023-09-30 | $-14.44 Million | $-42.97 Million | 2.976x | +145.88% |
| 2022-09-30 | $8.74 Million | $-56.67 Million | -6.487x | +44.91% |
| 2021-09-30 | $4.61 Million | $-54.25 Million | -11.776x | -4.69% |
| 2020-09-30 | $2.83 Million | $-31.79 Million | -11.249x | -475.20% |
| 2019-09-30 | $-10.77 Million | $-32.29 Million | 2.998x | +88.84% |
| 2018-09-30 | $-20.81 Million | $-33.04 Million | 1.588x | +214.62% |
| 2017-09-30 | $-30.73 Million | $-15.51 Million | 0.505x | -94.23% |
| 2016-09-30 | $-5.20 Million | $-45.48 Million | 8.746x | +649.60% |
| 2015-09-30 | $-23.55 Million | $-27.48 Million | 1.167x | +386.24% |
| 2014-09-30 | $-29.26 Million | $-7.02 Million | 0.240x | -- |